In this review, we use the term CH rather than clonal hematopoiesis of indeterminate potential (CHIP), as CHIP is defined by a VAF > 2% and by the absence of hematological disease, whereas our discussion includes ASXL1-mutated clones across a broader range of VAFs and clinical contexts.[4]. This evidence concerns the gene C4B and hematologic disorder.